IL-17A Blockade Treatment Success in Erythrodermic Pityriasis Rubra Pilaris

Wylie Masterson,Omar Pacha,Daniel Morse

doi:10.25251/skin.5.5.14

Abstract

Background: Pityriasis rubra pilaris is an inflammatory skin disease with no known etiology or treatment algorithm. PRP patients have an increase in cytokines IL-17A, IL-17F, and IL-22. There are case reports and series that study treatment with agents that block these cytokines, but more research is needed. Our objective is to add to the literature on treatment of PRP with IL-17A blockers. Case: A 63-year-old man presented with erythrodermic pityriasis rubra pilaris that was diagnosed after biopsy and laboratory tests ruled out other conditions such as psoriasis and Sezary syndrome. He was successfully treated with IL-17 blockade. Conclusion: Our case demonstrates the successful use of IL-17A blockade for PRP, which suggests that it could be an effective future treatment.

Highlights

IntroductionPityriasis rubra pilaris (PRP) is a rare inflammatory skin disease of unknown etiology and without a clear treatment algorithm
Our case demonstrates the successful use of IL-17A blockade for Pityriasis rubra pilaris (PRP), which suggests that it could be an effective future treatment
We present a case of new onset erythrodermic PRP successfully treated with IL-17A blockade

Summary

Introduction

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease of unknown etiology and without a clear treatment algorithm. The rash began four months earlier as an erythematous patch on the patient’s scalp which spread cephalocaudally to cover his entire body over the month He reported severe pruritus, worsening of the rash with sun exposure, and new alopecia on his parietal scalp. Case: A 63-year-old man presented with erythrodermic pityriasis rubra pilaris that was diagnosed after biopsy and laboratory tests ruled out other conditions such as psoriasis and Sezary syndrome. He was successfully treated with IL-17 blockade

Objectives

Discussion

Conclusion